Encore: Orchestra BioMed quickly nets another $34M for its cardiovascular pipeline

//Encore: Orchestra BioMed quickly nets another $34M for its cardiovascular pipeline

Encore: Orchestra BioMed quickly nets another $34M for its cardiovascular pipeline

Hot on the heels of inking an international distribution deal with Terumo, Orchestra BioMed has secured $34 million in new funding for its devices aimed at high blood pressure and blocked arteries. The series B-1 raise, and its previous series B round, also provide for follow-on investments of up to $57 million in the company. The latest preferred stock financing was led by Perceptive Advisors, RTW Investments and Soleus Capital, alongside additional backing from Terumo and previous investor SternAegis Ventures.

By | 2019-07-15T09:51:15-04:00 July 12th, 2019|News|Comments Off on Encore: Orchestra BioMed quickly nets another $34M for its cardiovascular pipeline

About the Author: